Is PSDV a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

459 people get PSDV articles and Market Currents by email alert.

Get email alerts on PSDV »

HEADLINES:

PSivida Corporation And GTx: 2 Of The Most Undervalued Biotechs For 2013
Bob's Stocks • Mon, May 20 • 4 Comments
pSivida Corp's CEO Discusses Q3 2013 Results - Earnings Call Transcript
Mon, May 13
pSivida Corp. Reports Third Quarter Fiscal Year 2013 Results

Business Wire (May 13, 2013)
Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013
Bob's Stocks • Mon, May 13 • 1 Comment
pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient Treated

Business Wire (May 7, 2013)
pSivida Corp. Announces Third Quarter 2013 Financial Results Release Date and Conference Call Information

Business Wire (May 6, 2013)
Ophthalmology: A Niche Where Innovation Pays
Richard Richter • Mon, May 6 • 1 Comment
pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013

Business Wire (May 1, 2013)
pSivida Reports ILUVIEN® Available in UK

Business Wire (Apr 29, 2013)
For Iluvien, The FDA Isn't The Issue; European Sales Are
Andreas Spiro • Wed, Apr 24 • 2 Comments
pSivida Announces Launch of New Online Corporate Communication Channels

Business Wire (Apr 10, 2013)
Is The Third Time The Charm For ILUVIEN?
David Sobek • Thu, Apr 4 • 1 Comment
pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company

Business Wire (Apr 4, 2013)
pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular Edema

Business Wire (Apr 1, 2013)
pSivida Reports Updates on ILUVIEN® for Planned Resubmission to FDA and European Launch

Business Wire (Mar 22, 2013)
pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference

Business Wire (Mar 20, 2013)
pSivida's CEO Discusses F2Q 2013 Results - Earnings Call Transcript
Wed, Feb 6 • 1 Comment
pSivida Corp. Reports Second Quarter Fiscal Year 2013 Results

Business Wire (Feb 6, 2013)
pSivida Corp. Announces Second Quarter 2013 Financial Results Release Date and Conference Call Information

Business Wire (Jan 30, 2013)
Psivida Corp. Announces Final Published Guidance from U.K.’s Nice and Pursuit of Patient Access Scheme for Iluvien® for DME

Business Wire (Jan 23, 2013)

To learn more about Seeking Alpha Pro, click here.

For Iluvien, The FDA Isn't The Issue; European Sales Are
Andreas Spiro • Wed, Apr 24 • 2 Comments
Psivida: Small-Cap Ophthalmology-Based BioTech Positioned For Long-Term Growth
Scott Matusow • Wed, Apr 18, 2012 • 6 Comments
Psivida Licensee Set For European Launch By Year's End
Len Zehr • Wed, Apr 11, 2012 • 1 Comment
Psivida on the Cusp of Big Breakthrough
Len Zehr • Tue, Jul 5, 2011 • 1 Comment
Psivida Shares Drop 20% -- Should Recover Soon (PSDV)
David Segelov • Tue, Jul 18, 2006 • 2 Comments
Psivida: A Biotech Platform With Great Potential (PSDV)
David Segelov • Thu, Jul 6, 2006 • 1 Comment

PSivida Corporation And GTx: 2 Of The Most Undervalued Biotechs For 2013
Bob's Stocks • Mon, May 20 • 4 Comments
Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013
Bob's Stocks • Mon, May 13 • 1 Comment
Ophthalmology: A Niche Where Innovation Pays
Richard Richter • Mon, May 6 • 1 Comment
Is The Third Time The Charm For ILUVIEN?
David Sobek • Thu, Apr 4 • 1 Comment
3 Dirt Cheap Drug Companies About To Make A Comeback
Louis Dematteis • Tue, Nov 6, 2012
5 Healthcare Companies With Insider Buying During October 2012
Markus Aarnio • Mon, Oct 15, 2012 • 2 Comments
Friday's BioPharma Watch List: Amarin's Vascepa Approval - What This Now Means
Scott Matusow • Fri, Jul 27, 2012 • 56 Comments
5 Rally Stocks: 2 To Buy, 2 To Sell, And 1 To Watch
Henry Kawabe • Fri, Jul 20, 2012 • 16 Comments
Bio Pharma Momentum Movers For Today: Will Arena's Weight Loss Drug Lorcaserin Be Approved?
Scott Matusow • Wed, Jun 27, 2012 • 52 Comments
Bio-Pharma Buy Out Speculation And Rumor Watch List
Scott Matusow • Mon, Apr 23, 2012 • 8 Comments
Tuesday's Bio-Pharma Watch List
Scott Matusow • Tue, Mar 27, 2012 • 11 Comments
Alimera, pSivida Strike Out On Eye Implant Drug
EP Vantage • Tue, Nov 15, 2011 • 2 Comments
5 Pharma Companies With November Catalysts
Spencer Knight • Tue, Nov 1, 2011 • 2 Comments
Upcoming FDA Approval Decision Dates for Q4 2011 - How You Can Profit
David Zanoni • Thu, Oct 6, 2011 • 9 Comments
7 Undervalued Stocks Exhibiting The Golden Cross
Kapitall • Tue, Sep 13, 2011
Biotech's Wild Ride for the Second Half of 2011
Michael J. Ray • Wed, Aug 3, 2011 • 7 Comments
3 Biotech Stocks With Upcoming PDUFA Dates to Buy
Alex Shadunsky • Mon, Jul 18, 2011 • 3 Comments
Upcoming PDUFA Dates for Sub-$5 Stocks
Alex Shadunsky • Tue, Jul 5, 2011 • 6 Comments
The Incredible Shrinking Eye Care Sector
Stephen Simpson • Tue, Apr 5, 2011 • 6 Comments
13 Above Average Stocks: Industry Leaders or Boat Anchors in Disguise?
Kurtis Hemmerling • Wed, Jan 26, 2011 • 1 Comment

pSivida Corp's CEO Discusses Q3 2013 Results - Earnings Call Transcript
Mon, May 13
pSivida's CEO Discusses F2Q 2013 Results - Earnings Call Transcript
Wed, Feb 6 • 1 Comment
pSivida's CEO Discusses F1Q13 Results - Earnings Call Transcript
Thu, Nov 8, 2012 • 1 Comment
pSivida's CEO Discusses F4Q2012 Results - Earnings Call Transcript
Mon, Sep 24, 2012 • 2 Comments
Psivida Ltd. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript
Thu, Feb 11, 2010

pSivida Corp. Reports Third Quarter Fiscal Year 2013 Results

Business Wire (May 13, 2013)
pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient Treated

Business Wire (May 7, 2013)
pSivida Corp. Announces Third Quarter 2013 Financial Results Release Date and Conference Call Information

Business Wire (May 6, 2013)
pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013

Business Wire (May 1, 2013)
pSivida Reports ILUVIEN® Available in UK

Business Wire (Apr 29, 2013)
pSivida Announces Launch of New Online Corporate Communication Channels

Business Wire (Apr 10, 2013)
pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company

Business Wire (Apr 4, 2013)
pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular Edema

Business Wire (Apr 1, 2013)
pSivida Reports Updates on ILUVIEN® for Planned Resubmission to FDA and European Launch

Business Wire (Mar 22, 2013)
pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference

Business Wire (Mar 20, 2013)
pSivida Corp. Reports Second Quarter Fiscal Year 2013 Results

Business Wire (Feb 6, 2013)
pSivida Corp. Announces Second Quarter 2013 Financial Results Release Date and Conference Call Information

Business Wire (Jan 30, 2013)
Psivida Corp. Announces Final Published Guidance from U.K.’s Nice and Pursuit of Patient Access Scheme for Iluvien® for DME

Business Wire (Jan 23, 2013)
pSivida Corp. Announces Spain Grants ILUVIEN® Marketing Approval for Chronic Diabetic Macular Edema

Business Wire (Jan 17, 2013)
pSivida Corp. Reports Patient Access Scheme Being Developed by Alimera to Address Cost Concerns Following Negative Final Draft Guidance by U.K.’s NICE for ILUVIEN® for DME

Business Wire (Nov 29, 2012)
pSivida Corp. Reports First Quarter Fiscal Year 2013 Results

Business Wire (Nov 8, 2012)
pSivida Corp Announces First Quarter 2013 Financial Results Release Date and Conference Call Information

Business Wire (Nov 1, 2012)
pSivida CEO to Discuss Sustained Delivery and Nanotechnology in Ophthalmology at Upcoming Massachusetts Biotechnology Council Meeting

Business Wire (Oct 15, 2012)
pSivida Corp. Reports Fourth Quarter and Fiscal Year 2012 Results

Business Wire (Sep 24, 2012)
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2012 Financial Results Release Date and Conference Call Information

Business Wire (Sep 17, 2012)

PSDV vs. ETF Alternatives

Company Description

Currently, there's no company description for PSDV.

Sector: Healthcare

Industry: Drug Delivery & Accessories

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 4:13 PM pSivida (PSDV): FQ3 EPS of -$0.12 beats by $0.01. Revenue of $513K misses by $137K. Shares +3.8% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Monday, April 29, 3:35 PM pSivida (PSDV +5%) gains today after its licensee Alimera Sciences (ALIM -3.2%) says Iluvien, its treatment for chronic diabetic macular edema, is now available in the UK for treatment of private pay and privately insured patients. Comment! [Healthcare, On the Move, Global & FX]
Thursday, April 4, 9:12 AM pSivida (PSDV) +12.8% premarket after saying it signed a funded technology evaluation agreement with a leading global pharmaceutical company, which will evaluate PSDV's proprietary Durasert and Tethadur technologies for the unnamed company's select products in ophthalmology. Comment! [Healthcare, On the Move]
Thursday, April 4, 9:10 AM Premarket gainers: CBMX +20%. PSDV +13%. NAVB +10%. ALU +9%. ARIA +6%.
Comment! [On the Move]
Friday, February 22, 12:53 PM Midday top 10 gainers: WBMD +25%. EDAP +24%. PSDV +24%. ARUN +22%. BLOX +17%. SSTK +16%. FIRE +15%. B +15%. AVG +12%. RKUS +12%.
Midday top 10 losers: ETRM -20%. MMSI -19%. WIFI -18%. FRO -14%. NVGN -12%. CBMX -12%. VOLC -11%. GMXR -16%. RCKY -11%. REED -11%. Comment! [On the Move]
Wednesday, February 6, 7:06 PM pSivida (PSDV): FQ2 EPS of -$0.11 beats by $0.02. Revenue of $585K misses by $15K. Shares -5.8% AH. (PR) 1 Comment [Earnings, Breaking News, Healthcare, On the Move]
Friday, February 1, 12:45 PM Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move]
Wednesday, December 19, 2012, 12:45 PM Midday top 10 gainers: AMPL +119%. DYNT +64%. EDAP +25%. ALTE +24%. STP +16%. PTNR +13%. LDK +12%. GBR +19%. CSUN +12%. ELTK +12%.
Midday top 10 Losers: ONTY -54%. CMGE -21%. PLXT -18%. NICK -15%. DLB -12%. PNTR -11%. PSDV -10%. EGLE -10%. CCUR -10%. PTEK -10%. Comment! [On the Move]
Friday, November 9, 2012, 12:41 PM pSivida (PSDV +3.5%) gains in spite of a mixed FQ1 report late yesterday. What's driving the move is its announcement that it's received FDA clearance to proceed on two pivotal Phase III clinical trials of its lead development product, an injectable micro-insert for posterior uveitis. The trials, scheduled to begin next year, will form the basis for a future NDA submission. (PR) 1 Comment [Healthcare, Earnings, On the Move]
Thursday, August 2, 2012, 1:08 PM Shares of pSivida (PSDV -12%) slide after it says it's entered into a securities purchase agreement with institutional investors to raise approximately $5.36M in a direct offering. The company plans to sell, in units, around 2.5M shares of common stock and warrants to purchase 624K shares of its common stock, at a price of $2.15 per unit. Comment! [Healthcare, On the Move]
Monday, July 30, 2012, 10:24 AM pSivida (PSDV +4.75%) signs a funded agreement in which a "leading global biopharmaceutical company" will assess pSivida's Tethadur technology in the field of ophthalmology. The deal is pSivida's first commercial agreement for Tethadur, which is used for delivering proteins and antibodies. (PR) Comment! [Healthcare, On the Move]
Thursday, July 26, 2012, 9:12 AM Premarket gainers: GENE +33%. PSDV +24%. IBIO +21%. S +18%. WDC +17%. AKAM +16%. PCS +14%. TEX +13%. FTNT +13%. STX +11%. WFM +11%. GNC +8%. UN +7%. CROX +7%. BBVA +7%. PHM +7%. SVU +6%. SAN +6%. PSTI +6%. EQIX +6%. ABB +6%. IOC +6%. AEM +6%. FTE +6%. MRVL +6%. NOK +5%. OVTI +5%.
Losers: ZNGA -40%. NG -29%. STRA -17%. GLUU -8%. IPG -6%. ESI -7%. GRPN -6%. FB -6%. ALU -6%. STB -6%. ABX -5%. LVS -5%. 1 Comment [On the Move]
Thursday, July 19, 2012, 10:27 AM pSivida (PSDV) rockets 41% after the FDA says it can skip Phase I and Phase II trials for an eye insert treatment and go straight to Phase III. The product injects a drug into the back of the eye to treat posterior uveitis, an inflammatory disease that is the third-biggest cause of blindness in the U.S. (PR) Comment! [On the Move, Healthcare]
Monday, February 27, 2012, 2:01 PM Microcaps Alimera Sciences (ALIM +32.1%) and pSivida (PSDV +21.8%) soar off of speculation that the EU will grant approval for eye disease drug Iluvien. 1 Comment [Healthcare, On the Move]
Friday, November 11, 2011, 1:39 PM Shares of Alimera Sciences (ALIM -72%) are crushed after the FDA fails to approve its Iluvien drug for the treatment of diabetic macular edema, stating that the risks of adverse reactions were "significant." Alimera will need to conduct two additional clinical trials to demonstrate that the product is safe and effective. Shares of Iluvien licensee pSivida (PSDV -54%) also sink. Comment! [Healthcare, On the Move]
Monday, December 27, 2010, 8:02 AM Alimera (ALIM) fell 29% in Thursday's AH trading after the FDA failed to approve its Iluvien drug and asked for more info, but Oppenheimer sees the weakness as a buying opportunity and expects Iluvien to eventually be approved. Comment!

Ryan Mallory
Fuinhaz Setups for April 4 2013 | $ALLT $BBRY $FB $FNSR $NUAN $PRXI $PSDV $SRPT $TSLA $ZNGA | SharePlanner http://bit.ly/10z0zPy
Apr 4, 9:20 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Listen to pSivida's (NASDAQ:PSDV) Q4 and fiscal year 2012 results today at 4:30 p.m. ET on my show @ http://bit.ly/xP8ArD
9/24/12
Reply (1)

• !Report Abuse
View all 1 replies
FredChen23: scott - did you end up listening to the CC? if so, what'd you think?
9/26/12
• !Report Abuse
Add a reply...

140 characters

abardy
PSDV is this a good entry point? This is considering dilution and negative news from the U.K.
8/16/12
Reply (2)

• !Report Abuse
View all 2 replies
DAG1996: don't know what the price was when u wrote this but i too am wondering if it's still worth buying and at what entry.
8/17/12
• !Report Abuse
DAG1996: dilution is to be expected but the UK news is concerning since it implies US approval is unlikely. wish there was more coverage/info.
8/17/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Alfred is the Mann! $MNKD $AMRN $MNOV $PCRX $PPHM $PSDV $SVNT #biotech #pharma #stocks #finance #speculation http://seekingalpha.com/a/h4r3
8/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

johnjail
finally taken a position in PSDV at 2.15, good price.
8/2/12
Reply (20)

• !Report Abuse
View all 20 replies
johnjail: they have good partnership, pfizer, baush e lomb and http://bit.ly/O8Ltfg . surely UK news are bad as regards also US approvals
8/10/12
• !Report Abuse
DAG1996: ok thanks for the good info. good luck.
8/10/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV Announces Germany Grants ILUVIEN Marketing Authorization for the Treatment of Chronic D-Macular Edema @ http://yhoo.it/MIhtcJ
7/26/12
Reply (2)

• !Report Abuse
View all 2 replies
moni74: Scott, are you still with the short term goal of $5 with PSTI? its does not seem to hold the price. Did you sell your position? Thanks
7/26/12
• !Report Abuse
rseiter: This a wild one...caught the last wave, got in at 2.45 and out at 3.00 in a matter of days
8/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV has good news this am.. I maintain that one is one of the best LONG TERM small cap investments around, Top management = execution
7/19/12
Reply (6)

• !Report Abuse
View all 6 replies
Scott Matusow: good going Huan--hope u made a lot of money!
7/20/12
• !Report Abuse
lilvj83: i bought this at 3.10 yesterday..whats your thoughts? I am afraid losing money
7/20/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV News at http://yhoo.it/MAn7Ky
6/28/12
Reply (5)

• !Report Abuse
View all 5 replies
RyRy: I don't understand your interest in this stock. there is no volume. ??
6/29/12
• !Report Abuse
Scott Matusow: because its a well run company with honest and smart management.
6/29/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
on $PSDV, remember, because warrants expire unexercised at 7.98, those holders have shorted to protect downside
6/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$PSDV breaking thru 2.60 resistance, tried to tell you guys on this one :)
6/27/12
Reply (2)

• !Report Abuse
View all 2 replies
micmac: Scott, appreciate the coverage on PSDV. Been a holder through the rough times. I do believe PFE actually owns 9.98 % of PSDV, rather than 7%
7/24/12
• !Report Abuse
Scott Matusow: they have more now? i was not aware, my bad.. good little company, give them time, I will bet they execute, bought family account 10,000 LT
7/24/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
Listen to pSivida's (NASDAQ:PSDV) Q4 and fiscal year 2012 results today at 4:30 p.m. ET on my show @ http://bit.ly/xP8ArD
9/24/12
Reply (1)

• !Report Abuse
View all 1 replies
FredChen23: scott - did you end up listening to the CC? if so, what'd you think?
9/26/12
• !Report Abuse
Add a reply...

140 characters

abardy
PSDV is this a good entry point? This is considering dilution and negative news from the U.K.
8/16/12
Reply (2)

• !Report Abuse
View all 2 replies
DAG1996: don't know what the price was when u wrote this but i too am wondering if it's still worth buying and at what entry.
8/17/12
• !Report Abuse
DAG1996: dilution is to be expected but the UK news is concerning since it implies US approval is unlikely. wish there was more coverage/info.
8/17/12
• !Report Abuse
Add a reply...

140 characters

johnjail
finally taken a position in PSDV at 2.15, good price.
8/2/12
Reply (20)

• !Report Abuse
View all 20 replies
johnjail: they have good partnership, pfizer, baush e lomb and http://bit.ly/O8Ltfg . surely UK news are bad as regards also US approvals
8/10/12
• !Report Abuse
DAG1996: ok thanks for the good info. good luck.
8/10/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV Announces Germany Grants ILUVIEN Marketing Authorization for the Treatment of Chronic D-Macular Edema @ http://yhoo.it/MIhtcJ
7/26/12
Reply (2)

• !Report Abuse
View all 2 replies
moni74: Scott, are you still with the short term goal of $5 with PSTI? its does not seem to hold the price. Did you sell your position? Thanks
7/26/12
• !Report Abuse
rseiter: This a wild one...caught the last wave, got in at 2.45 and out at 3.00 in a matter of days
8/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV breaking thru 2.60 resistance, tried to tell you guys on this one :)
6/27/12
Reply (2)

• !Report Abuse
View all 2 replies
micmac: Scott, appreciate the coverage on PSDV. Been a holder through the rough times. I do believe PFE actually owns 9.98 % of PSDV, rather than 7%
7/24/12
• !Report Abuse
Scott Matusow: they have more now? i was not aware, my bad.. good little company, give them time, I will bet they execute, bought family account 10,000 LT
7/24/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV has good news this am.. I maintain that one is one of the best LONG TERM small cap investments around, Top management = execution
7/19/12
Reply (6)

• !Report Abuse
View all 6 replies
Scott Matusow: good going Huan--hope u made a lot of money!
7/20/12
• !Report Abuse
lilvj83: i bought this at 3.10 yesterday..whats your thoughts? I am afraid losing money
7/20/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV News at http://yhoo.it/MAn7Ky
6/28/12
Reply (5)

• !Report Abuse
View all 5 replies
RyRy: I don't understand your interest in this stock. there is no volume. ??
6/29/12
• !Report Abuse
Scott Matusow: because its a well run company with honest and smart management.
6/29/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ALIM, $ARNA, $AEZS, $ATRS, $PSDV mentioned in my new article due out pre market today.
6/27/12
Reply (10)

• !Report Abuse
View all 10 replies
onehardroll: Phemale60, it's still going down......when will we know if it's approved or not?
6/27/12
• !Report Abuse
nkimidi: Hi Scott, what is a good price to buy ATRS?
6/27/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Something might be up with $PSDV besides the relation to $ALIM, I know they are working on things, and the time is right for news
6/26/12
Reply (7)

• !Report Abuse
View all 7 replies
counsel0857: Personally I think ATRS is doing great. If I hadn't gone all-in in OMPI I would load the boat on ATRS. A "down" day like this is expected!
6/26/12
• !Report Abuse
stncws1: i will grab some ATRS when down day approached
6/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I think I will mention $PSDV tomorrow, something going on it seems
6/26/12
Reply (3)

• !Report Abuse
View all 3 replies
breaka40: how did we miss supn?? I didn't see it on the fda sites or anything..
6/26/12
• !Report Abuse
DANDISIK: WOW! $SUPN was up 114% today. To anyone who owned the stock congratulations, you made out big time. Personally I never heard of the company.
6/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PSDV looks based, should begin to move up slowly, I think more news might be coming there.
4/26/12
Reply (6)

• !Report Abuse
View all 6 replies
Scott Matusow: yes, but cost basis average in, unless u want a smaller block
4/26/12
• !Report Abuse
gafigal: will go in for more PSDV and/or IBIO monday (1K more apiece?)
4/27/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I know I keep talking about $PSDV, and I don't own any because of money in $ATRS, but its the most undervalued co in the sector.
4/24/12
Reply (7)

• !Report Abuse
View all 7 replies
Scott Matusow: no, thats expected old news. PFE will be the buyer :)
4/26/12
• !Report Abuse
Noreika: Thanks again Scott. ATRS is looking good again this am.
4/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
kind of interesting people cant see an obvious buy-out in my opinion coming with $PSDV
4/24/12
Reply (16)

• !Report Abuse
View all 16 replies
cornerback2006: Sorry boss, Moved convo to your inbox..Check your mail And no, not waiting on money, I am def long this co
4/25/12
• !Report Abuse
cornerback2006: So many other catalysts happening these last few days of month, sensory overload! Plus, May is only few days away :-)
4/25/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Looks like its possible $PSDV hits 3 bucks a share today. Investors I think can figure that one out :)
4/24/12
Reply (14)

• !Report Abuse
View all 14 replies
wiesemc: Or Gordon Gekko.
4/24/12
• !Report Abuse
Scott Matusow: " you once told me Gordon not to get emotional over stocks, DON'T"
4/24/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ACHN $PSDV could be on move today up. ACHN oversold reaction, In my opinion nice entry, PSDV under accumulation, buy out candidate.
4/20/12
Reply (1)

• !Report Abuse
View all 1 replies
cornerback2006: I bought in on ACHN, hoping they announce good Phase II results b/n now and Sunday, especially w/ the knee-jerk reaction yesterday...
4/20/12
• !Report Abuse
Add a reply...

140 characters

PSDV pSivida Corp.

PSDV

pSivida Corp.